Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    NanoViricides Inc.

    AMEX: NNVC · Real-Time Price · USD
    1.35
    -0.06 (-4.26%)
    At close: May 09, 2025, 3:10 PM
    -4.26%
    Bid 1.32
    Market Cap 21.07M
    Revenue (ttm) n/a
    Net Income (ttm) -9.36M
    EPS (ttm) -0.71
    PE Ratio (ttm) -1.9
    Forward PE -1.12
    Analyst Buy
    Ask 1.37
    Volume 116,481
    Avg. Volume (20D) 159,247
    Open 1.44
    Previous Close 1.41
    Day's Range 1.28 - 1.44
    52-Week Range 0.94 - 3.59
    Beta 0.95

    About NNVC

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol NNVC
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for NNVC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    7 months ago
    +5.19%
    NanoViricides shares are trading higher after the ... Unlock content with Pro Subscription
    10 months ago
    +4.05%
    NanoViricides shares are trading higher after the company announced it discussed its development program for NV-387.
    news image

    22 hours ago · proactiveinvestors.com

    NanoViricides wins ethics approval for Phase II Mpox drug trial in DRC

    NanoViricides (NYSE-A:NNVC) said on Thursday it has received ethics committee approval in the Democratic Republic of Congo to move forward with a planned Phase II clinical trial of its antiviral drug ...

    news image

    1 day ago · accessnewswire.com

    Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo

    SHELTON, CT / ACCESS Newswire / May 8, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company") today reported that it has received approval from the National Ethics Committee for Health (CNES) of...

    news image

    4 days ago · newsfilecorp.com

    NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC

    Shelton, Connecticut--(Newsfile Corp. - May 5, 2025) - NanoViricides, Inc. (NYSE American: NNVC), (the "Company"), a leading clinical stage global pioneer in the development of broad-spectrum antivira...

    news image

    1 week ago · proactiveinvestors.com

    NanoViricides advances measles drug development amid rising US cases

    NanoViricides (NYSE-A:NNVC) said it is moving forward with the development of a drug to treat measles, as US health officials report a continuing rise in infections amid declining vaccination rates. T...

    news image

    1 week ago · accessnewswire.com

    Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It

    SHELTON, CT / ACCESS Newswire / April 29, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a leading global pioneer in the development of broad-spectrum ant...

    news image

    3 weeks ago · proactiveinvestors.com

    NanoViricides evaluating antiviral drug NV-387 for measles treatment

    NanoViricides (NYSE-A:NNVC) has begun evaluating its clinical-stage antiviral NV-387 for the treatment of measles, a disease with no currently approved drug treatment. “A drug for measles is at presen...

    news image

    3 weeks ago · accessnewswire.com

    Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak

    SHELTON, CT / ACCESS Newswire / April 14, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a leading global pioneer in the development of broad-spectrum ant...

    news image

    1 month ago · proactiveinvestors.com

    NanoViricides unaffected by US tariff turmoil, says CFO

    NanoViricides (NYSE-A:NNVC) chief financial officer Meeta Vyas talked with Proactive about the company's progress developing broad-spectrum antiviral therapeutics and how its technology remains unaffe...

    news image

    1 month ago · proactiveinvestors.com

    NanoViricides eyes role in US bird flu fight as USDA unveils $100M initiative

    The US Department of Agriculture (USDA) will invest up to $100 million to combat highly pathogenic avian influenza (HPAI), funding research into prevention, therapeutics, and vaccine candidates, the a...

    news image

    1 month ago · proactiveinvestors.com

    NanoViricides says business unaffected by US tariffs, highlights antiviral pipeline

    NanoViricides (NYSE-A:NNVC) said on Tuesday that its business remains unaffected by US government tariffs, retaliatory trade policies, or federal spending cuts. In a statement, the clinical-stage biot...

    Add to Watchlist